You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Atomoxetine improves teacher rated symptoms in children with ADHD more than placebo

http://dx.doi.org/10.1136/ebmh.9.1.7

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:647–55.OpenUrlCrossRefPubMedWeb of Science

    Q Is once-daily atomoxetine more effective than placebo at reducing attention deficit hyperactivity disorder (ADHD) symptoms displayed at school?

    METHODS

    Embedded ImageDesign:

    Multicentre randomised controlled trial.

    Embedded ImageAllocation:

    Concealed.

    Embedded ImageBlinding:

    Double blind.

    Embedded ImageFollow up period:

    Seven weeks.

    Embedded ImageSetting:

    Eight sites in the USA, two in Canada, and one in Puerto Rico.

    Embedded ImagePatients:

    153 children aged 8–12 years with ADHD (DSM-IV); with symptom severity on the investigator administered ADHD Rating Scale-IV-Teacher Version (ADHDRS-IV-Teacher:Inv) at least 1.0 standard deviation (SD) above age and gender norms, and at least 1.5 SD above norms on …

    View Full Text

    Footnotes

    • For correspondence: Dr A J Allen, Lilly Corporate Center, Indianapolis, IN 46285, USA; allenaj{at}lilly.com

    • Sources of funding: Eli Lilly and Company.